<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041296</url>
  </required_header>
  <id_info>
    <org_study_id>534/20</org_study_id>
    <nct_id>NCT05041296</nct_id>
  </id_info>
  <brief_title>Cardiac MRI for Detection of Acute and Chronic Cardiac Involvement in Patients With Epilepsy</brief_title>
  <official_title>The Epileptic Heart - Multiparametric Cardiac Magnetic Resonance Imaging for Detection and Quantification of Acute and Chronic Cardiac Involvement in Patients With Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to use multiparametric cardiac MRI to identify any abnormalities in&#xD;
      myocardial structure and function in patients with epilepsy. A two-stage study design is&#xD;
      planned as part of the study:&#xD;
&#xD;
        1. In the acute setting, cardiac MRI will be performed in patients before and after a&#xD;
           tonic-clonic seizure and compared intraindividually. In this study arm, potential acute&#xD;
           seizure-induced myocardial damage will be detected.&#xD;
&#xD;
        2. In the chronic setting, cardiac MRI will be performed in patients with known chronic&#xD;
           epilepsy during the seizure-free interval to detect potential chronic myocardial damage&#xD;
           (myocardial fibrosis) and compared with a control population. Within the group of&#xD;
           epilepsy patients, possible associations with various epilepsy-specific characteristics&#xD;
           (e.g., form, cause, onset, duration, and severity of epilepsy) will be investigated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>T1 relaxation time</measure>
    <time_frame>Measurement will be performed within 2 weeks after MRI scan.</time_frame>
    <description>T1 relaxation times will be obtained to asses acute myocardial injury and fibrosis. T1 maps will be analyzed using a segmental approach by region of interest analysis. T1 relaxation times are given in [ms].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T2 relaxation time</measure>
    <time_frame>Measurement will be performed within 2 weeks after MRI scan.</time_frame>
    <description>T2 relaxation times will be obtained to asses myocardial edema. T2 maps will be analyzed using a segmental approach by region of interest analysis. T2 relaxation times are given in [ms].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracellular volume fraction</measure>
    <time_frame>Measurement will be performed within 2 weeks after MRI scan.</time_frame>
    <description>Myocardial extracellular volume will be obtained to asses extracellular space/myocardial fibrosis. ECV values will be calculated using a segmental approach by region of interest analysis of native and contrast-enhanced T1 relaxation maps. ECV values are given in [%].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial strain</measure>
    <time_frame>Measurement will be performed within 2 weeks after MRI scan.</time_frame>
    <description>Cardiac magnetic resonance feature-tracking will be used to asses left ventricular longitudinal, circumferential and radial strain (Strain values are given in [%]).</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Epilepsy</condition>
  <condition>Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>Chronic group</arm_group_label>
    <description>Chronic epilepsy with recurrent seizures</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute group</arm_group_label>
    <description>Epilepsy and short-term history of seizures</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Healthy participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac magnetic resonance scan</intervention_name>
    <description>Multiparametric cardiac magnetic resonance including traditional and quantitative functional and structural parameters</description>
    <arm_group_label>Acute group</arm_group_label>
    <arm_group_label>Chronic group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with epilepsy with treatment in the Clinic and Polyclinic for Epileptology of the&#xD;
        University Hospital Bonn (Primary care clinic)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. diagnosed epilepsy&#xD;
&#xD;
          2. examination under usual antiepileptic pharmacotherapy or medication up-dosing (if&#xD;
             medication was reduced during video-EEG recording)&#xD;
&#xD;
          3. age between 18-60 years&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. underlying cardiac disease, e.g. coronary artery disease, previous myocardial&#xD;
             infarction, previous myocarditis, complex congenital heart defect, known&#xD;
             cardiomyopathy of other cause&#xD;
&#xD;
          2. pregnant and breastfeeding women&#xD;
&#xD;
          3. patients who use IUD for contraception&#xD;
&#xD;
          4. patients with a contraindication to contrast enhanced MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Julian A. Luetkens, PD Dr.</last_name>
    <phone>+49 228 287 19860</phone>
    <email>julian.luetkens@ukbonn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Isaak, Dr.</last_name>
    <phone>+49 228 287 15960</phone>
    <email>alexander.isaak@ukbonn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Bonn, Clinic and Polyclinic for Epileptology</name>
      <address>
        <city>Bonn</city>
        <state>NRW</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Surges, Prof.</last_name>
      <phone>+49 228 287 15727</phone>
      <email>rainer.surges@ukbonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn, Clinic for Diagnostic and Interventional Radiology</name>
      <address>
        <city>Bonn</city>
        <state>NRW</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian A Luetkens, PD Dr.</last_name>
      <email>julian.luetkens@ukbonn.de</email>
    </contact>
    <contact_backup>
      <last_name>Alexander Isaak, Dr.</last_name>
      <email>alexander.isaak@ukbonn.de</email>
    </contact_backup>
    <investigator>
      <last_name>Julian A Luetkens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Julian Alexander Luetkens</investigator_full_name>
    <investigator_title>Principal Investigator, Senior Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

